GlaxoSmithKline, the London-based pharmaceutical giant with a substantial presence in Montgomery County and Philadelphia, announced a landmark investment of up to $800 million to expand its Pennsylvania manufacturing operations, reports John George for the Philadelphia Business Journal.

This new GSK expansion, located in Marietta, Lancaster County, marks GSK’s largest U.S. manufacturing investment to date and is expected to create 200 new jobs.

Pennsylvania is supporting the project with a historic $21 million funding package, including $18 million from the Redevelopment Assistance Capital Program, a $2.35 million Pennsylvania First grant, and a $645,000 WEDnet grant for employee training. State officials, including Rick Siger, Secretary of the Department of Community and Economic Development, highlighted this investment as part of Governor Josh Shapiro’s strategy to grow Pennsylvania’s life sciences sector, which includes nearly 3,100 companies.

The planned 300,000-square-foot facility will produce sterile vaccines and medicines, support research and development for clinical trials, and establish a new vaccines plant dedicated to GSK’s MAPS technology, pending regulatory approval. GSK will also renovate existing buildings on its Marietta campus, aiming to double the site’s operational capacity.

With over 4,000 employees in the Philadelphia region, including Upper Providence in Montgomery County, GSK’s commitment underscores the region’s significance in the life sciences industry. Construction begins later this year, with facility completion anticipated by 2028, establishing Marietta as a critical hub for next-generation medical innovations.

Read more about GSK’s expansion at the Philadelphia Business Journal.